PALISADE BIO, INC.
For the period ended May 12, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
May 12, 2026 · Filed May 12, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Well-Capitalized Through Potential Key Value Inflection Points
Well-Capitalized Through Potential Key Value Inflection Points
o
Phase 2 UC readout (expected in 2H 2027)
o
Phase 2 CD readout (expected early 2028)
PALI-2108 is an orally administered, once-daily PDE4 inhibitor prodrug designed for targeted activation in the ileum and colon. Its localized bioactivation is intended to enable sustained target inhibition at the site of inflammation while minimizing systemic exposure and improving tolerability.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.